Home›Clinical trials›Fibrosis Lessens After Metabolic Surgery

A study testing whether a new weekly shot, tirzepatide, can help people reduce liver fat.

Recruiting now. Registry record last updated July 31, 2026.

Who can join
Adults 18 to 75, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis), BMI 35+.
What you take
tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 5.4 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 4Sponsor The Cleveland ClinicDrug tirzepatideClass GLP-1/GIPSites 4 USEnrollment target 120

What this study is for

Primary condition: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Also studied in: Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity.

Full scientific study title: Fibrosis Lessens After Metabolic Surgery.

Who can join

Age18 to 75SexAnyBMI35 to 70

Adults 18 to 75, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis), BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Is a candidate for general anesthesia
  • Is eligible for metabolic surgery (RYGB or SG) based on the ASMBS/IFSO 2022 guidelines
  • Has insurance coverage for metabolic surgery (the requirements may vary in each country)
  • Is ≥18 and ≤75 years old at the time of signing the informed consent
  • Has a BMI ≥35 and ≤70 kg/m2 at the time of first study visit

Key exclusion criteria

  • Known history of other chronic liver diseases (drug induced, viral hepatitis, autoimmune, and genetic):
  • Hepatitis B as detected by presence of hepatitis B surface antigen (HBsAg)
  • Hepatitis C as detected by presence of hepatitis C virus (HCV) RNA (in case the screening test for hepatitis C is positive, the confirmative test is decisive)
  • Autoimmune liver disease as diagnosed by antibodies or compatible liver histology
  • Primary biliary cirrhosis as defined by the presence of at least 2 criteria (elevated alkaline phosphatase, presence of anti-mitochondrial antibody, and histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)

Where this trial is enrolling

This trial has 4 sites across 4 states. Contact a site coordinator directly to start screening.

Arizona1 site
Indiana1 site
Minnesota1 site
Ohio1 site

Timeline

Started enrolling: July 11, 2024. Expected completion: December 31, 2029. Last updated on ClinicalTrials.gov: July 31, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.